Menu
sharewise sharewise
Log in
Sign up
Log in
Sign up
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.
Get an introduction to all features of this page

Heidelberg Pharma AG Stock

Price
Target price
€2.98

€2.98

-2.950%
-0.09
-2.950%
-

-

 
Buy 2 Sell 0
Buy 2
Sell 0
26.01.26 / Tradegate WKN: A11QVV / Name: Heidelberg Pharma / Stock / Biotechnology & Medical Research / Micro Cap /
Latest predictions
15.07.25
-35.64%
buy
02.03.25
6.43%
buy
Show more
Your prediction
Pros and Cons of Heidelberg Pharma AG in the next few years
Wizard

Financial data and news for Heidelberg Pharma

sharewise wants to provide you with the best news and tools for Heidelberg Pharma, so we directly link to the best financial data sources.

Financials

News

Broker

 

News

EQS-News: Heidelberg Pharma: Letter from the CEO
EQS-News: Heidelberg Pharma: Letter from the CEO
EQS-News: Heidelberg Pharma: Letter from the CEO
eqs_en 
0 17.12.25
EQS-News: Heidelberg Pharma Announces Changes to the Executive Management Board – Dr Dongzhou Jeffery Liu Appointed as Chairman of the Executive Board and Chief Executive Officer
EQS-News: Heidelberg Pharma Announces Changes to the Executive Management Board – Dr Dongzhou Jeffery Liu Appointed as Chairman of the Executive Board and Chief Executive Officer
EQS-News: Heidelberg Pharma Announces Changes to the Executive Management Board – Dr Dongzhou Jeffery Liu Appointed as Chairman of the Executive Board and Chief Executive Officer
eqs_en 
0 24.11.25
EQS-Adhoc: Heidelberg Pharma Announces Changes to the Executive Management Board - Dr Dongzhou Jeffery Liu Appointed as Chairman of the Executive Board and Chief Executive Officer
EQS-Adhoc: Heidelberg Pharma Announces Changes to the Executive Management Board - Dr Dongzhou Jeffery Liu Appointed as Chairman of the Executive Board and Chief Executive Officer
EQS-Adhoc: Heidelberg Pharma Announces Changes to the Executive Management Board - Dr Dongzhou Jeffery Liu Appointed as Chairman of the Executive Board and Chief Executive Officer
eqs_en 
0 24.11.25
EQS-News: Heidelberg Pharma’s Lead ATAC Candidate HDP-101 Shows Progress in Phase I/IIa Trial in Multiple Myeloma
EQS-News: Heidelberg Pharma’s Lead ATAC Candidate HDP-101 Shows Progress in Phase I/IIa Trial in Multiple Myeloma
EQS-News: Heidelberg Pharma’s Lead ATAC Candidate HDP-101 Shows Progress in Phase I/IIa Trial in Multiple Myeloma
eqs_en 
0 06.11.25
EQS-News: Heidelberg Pharma to Present New Clinical Data of Lead ADC Candidate HDP-101 at the World ADC Congress 2025 and to Host Webinar
EQS-News: Heidelberg Pharma to Present New Clinical Data of Lead ADC Candidate HDP-101 at the World ADC Congress 2025 and to Host Webinar
EQS-News: Heidelberg Pharma to Present New Clinical Data of Lead ADC Candidate HDP-101 at the World ADC Congress 2025 and to Host Webinar
eqs_en 
0 03.11.25
EQS-News: Heidelberg Pharma’s Lead ADC Candidate HDP-101 Granted Fast Track Designation by US FDA for the Treatment of Multiple Myeloma
EQS-News: Heidelberg Pharma’s Lead ADC Candidate HDP-101 Granted Fast Track Designation by US FDA for the Treatment of Multiple Myeloma
EQS-News: Heidelberg Pharma’s Lead ADC Candidate HDP-101 Granted Fast Track Designation by US FDA for the Treatment of Multiple Myeloma
eqs_en 
0 23.10.25
EQS-News: Heidelberg Pharma Reports on the First Nine Months of Financial Year 2025
EQS-News: Heidelberg Pharma Reports on the First Nine Months of Financial Year 2025
EQS-News: Heidelberg Pharma Reports on the First Nine Months of Financial Year 2025
eqs_en 
0 09.10.25
EQS-Adhoc: Heidelberg Pharma AG Announces Updated Guidance
EQS-Adhoc: Heidelberg Pharma AG Announces Updated Guidance
EQS-Adhoc: Heidelberg Pharma AG Announces Updated Guidance
eqs_en 
0 06.10.25
EQS-News: Heidelberg Pharma Advances to Cohort 9 in Phase I/IIa Trial of Lead ATAC Candidate HDP-101 in Multiple Myeloma
EQS-News: Heidelberg Pharma Advances to Cohort 9 in Phase I/IIa Trial of Lead ATAC Candidate HDP-101 in Multiple Myeloma
EQS-News: Heidelberg Pharma Advances to Cohort 9 in Phase I/IIa Trial of Lead ATAC Candidate HDP-101 in Multiple Myeloma
eqs_en 
0 25.09.25
EQS-News: Heidelberg Pharma Significantly Reduces Operating Costs and Focuses on Lead ADC Candidate HDP-101 Due to Delayed Milestone Payment
EQS-News: Heidelberg Pharma Significantly Reduces Operating Costs and Focuses on Lead ADC Candidate HDP-101 Due to Delayed Milestone Payment
EQS-News: Heidelberg Pharma Significantly Reduces Operating Costs and Focuses on Lead ADC Candidate HDP-101 Due to Delayed Milestone Payment
eqs_en 
0 25.09.25
EQS-Adhoc: Heidelberg Pharma Significantly Reduces Operating Costs and Focuses on Lead ADC Candidate HDP-101 Due to Delayed Milestone Payment
EQS-Adhoc: Heidelberg Pharma Significantly Reduces Operating Costs and Focuses on Lead ADC Candidate HDP-101 Due to Delayed Milestone Payment
EQS-Adhoc: Heidelberg Pharma Significantly Reduces Operating Costs and Focuses on Lead ADC Candidate HDP-101 Due to Delayed Milestone Payment
eqs_en 
0 25.09.25
EQS-News: Heidelberg Pharma Announces New Clinical Data on Lead ATAC Candidate HDP-101 to be Presented at International Myeloma Society Annual Meeting 2025
EQS-News: Heidelberg Pharma Announces New Clinical Data on Lead ATAC Candidate HDP-101 to be Presented at International Myeloma Society Annual Meeting 2025
EQS-News: Heidelberg Pharma Announces New Clinical Data on Lead ATAC Candidate HDP-101 to be Presented at International Myeloma Society Annual Meeting 2025
eqs_en 
0 04.09.25
EQS-Adhoc: Heidelberg Pharma’s Partner Telix Pharmaceuticals Gives Regulatory Update for its Imaging Agent TLX250-CDx
EQS-Adhoc: Heidelberg Pharma’s Partner Telix Pharmaceuticals Gives Regulatory Update for its Imaging Agent TLX250-CDx
EQS-Adhoc: Heidelberg Pharma’s Partner Telix Pharmaceuticals Gives Regulatory Update for its Imaging Agent TLX250-CDx
eqs_en 
0 28.08.25